Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study

• Published in: Central European journal of urology Vol. 72; no. 1; pp. 44 - 50
• Main Authors: Pogula, Vedamurthy Reddy, Kadiyala, Lalith Sagar, Gouru, Vijayabhaskar Reddy, Challa, Sivasankar Reddy, Byram, Ranadheer, Bodduluri, Sudeep
• Format: Journal Article
• Language: English
• Published: Poland Polish Urological Association 2019
• Subjects: Age; Bladder; Cancer surgery; Hyperplasia; Independent sample; Original Paper; Prostate cancer; Quality of life; Statistical analysis; Urinary tract infections; Urine; Urogenital system; United States > US; tadalafil; lower urinary tract symptoms; tamsulosin; benign prostatic hyperplasia
• DOI: 10.5173/ceju.2019.1570
• ISSN: 2080-4806

To compare the efiicacy of tadalafil 5 mg with tamsulosin 0.4 mg in the treatment of Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). A randomized prospective study on patients diagnosed with LUTS secondary to BPH with 50 patients in each group. Duration of the study is 12 weeks. Drug was given 30 min after dinner. Patients were assessed at baseline 1, 4 and 12 weeks with efficacy measures being Maximum flow rate (Qmax), Postvoid residual urine (PVR), International Prostate Symptom Score (IPSS), International Prostate Symptom Score Quality of life (IPSS QoL) and Sexual Health Inventory for Men (SHIM) scoring. Statistical analysis was done using paired sample t test and independent sample t test. In tadalafil group, 12 (24%) patients were having mild LUTS and 38 (76%) were having moderate LUTS. In tamsulosin group, 9 (18%) patients were having mild LUTS and 41 (82%) patients were having moderate LUTS. Seventeen patients in tadalafil group had associated ED (erectile dysfunction) and 13 patients had associated ED in tamsulosin group. When both groups were compared, tamsulosin showed better efficacy than tadalafil in treating LUTS secondary to BPH.